{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:15Z","timestamp":1791065295322,"version":"4.1.0"},"reference-count":191,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Endocrinol Diabetes"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>The therapeutic potential of venom-derived drugs is evident today. Currently, several significant drugs are FDA approved for human use that descend directly from animal venom products, with others having undergone, or progressing through, clinical trials. In addition, there is growing awareness of the important cosmeceutical application of venom-derived products. The success of venom-derived compounds is linked to their increased bioactivity, specificity and stability when compared to synthetically engineered compounds. This review highlights advancements in venom-derived compounds for the treatment of diabetes and related disorders. Exendin-4, originating from the saliva of Gila monster lizard, represents proof-of-concept for this drug discovery pathway in diabetes. More recent evidence emphasises the potential of venom-derived compounds from bees, cone snails, sea anemones, scorpions, snakes and spiders to effectively manage glycaemic control. Such compounds could represent exciting exploitable scaffolds for future drug discovery in diabetes, as well as providing tools to allow for a better understanding of cell signalling pathways linked to insulin secretion and metabolism.<\/jats:p>","DOI":"10.1177\/11795514211006071","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T10:20:22Z","timestamp":1616840422000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":46,"title":["Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes"],"prefix":"10.1177","volume":"14","author":[{"given":"Aimee","family":"Coulter-Parkhill","sequence":"first","affiliation":[{"name":"Diabetes Research Group, Ulster University, Coleraine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McClean","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, Ulster University, Coleraine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A","family":"Gault","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, Ulster University, Coleraine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Irwin","sequence":"additional","affiliation":[{"name":"Diabetes Research Group, Ulster University, Coleraine, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"bibr1-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2017.09.029"},{"key":"bibr2-11795514211006071","volume":"42","author":"King G.","year":"2015","journal-title":"Chem Sci"},{"key":"bibr3-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114096"},{"key":"bibr4-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200300628"},{"key":"bibr5-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.8255"},{"key":"bibr6-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/bi00815a005"},{"key":"bibr7-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1177\/106002808101501203"},{"key":"bibr8-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/bi00798a004"},{"key":"bibr9-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92958-0"},{"key":"bibr10-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02599.x"},{"key":"bibr11-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90722-9"},{"key":"bibr12-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01991.x"},{"key":"bibr13-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1177\/106002808602000301"},{"key":"bibr14-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.10.1423"},{"key":"bibr15-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(82)90351-4"},{"key":"bibr16-11795514211006071","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043363884"},{"key":"bibr17-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(90)90318-X"},{"key":"bibr18-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100406200"},{"key":"bibr19-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31821950c2"},{"key":"bibr20-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2018.05.009"},{"key":"bibr21-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)77710-2"},{"key":"bibr22-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)47710-1"},{"key":"bibr23-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.80.6.1766"},{"key":"bibr24-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/jm00042a007"},{"key":"bibr25-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110448"},{"key":"bibr26-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)92826-7"},{"key":"bibr27-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.4.437"},{"key":"bibr28-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(99)70075-X"},{"key":"bibr29-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/BF00630151"},{"key":"bibr30-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(76)45057-7"},{"key":"bibr31-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03916.x"},{"key":"bibr32-11795514211006071","first-page":"442","volume-title":"Consultative Haemostasis and Thrombosis","author":"Theodore E","year":"2013","edition":"3"},{"key":"bibr33-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.119374"},{"key":"bibr34-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.28087"},{"key":"bibr35-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000737"},{"key":"bibr36-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(76)45021-8"},{"key":"bibr37-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/16.21.10377"},{"key":"bibr38-11795514211006071","first-page":"1663","volume":"251","author":"Holleman WH","year":"1976","journal-title":"J Biochem"},{"key":"bibr39-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648004"},{"key":"bibr40-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e328040c0f2"},{"key":"bibr41-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-018-1718-y"},{"key":"bibr42-11795514211006071","author":"Bastos EMAF","year":"2011","journal-title":"WO\/2011\/041865 patent application"},{"key":"bibr43-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01132"},{"key":"bibr44-11795514211006071","unstructured":"ClinicalTrials.gov, Christopher MH. Apitox, honeybee toxin for pain and inflammation of osteoarthritis. National Library of Medicine (US) Identi-fier [NCT01112722]. 2016. Accessed August 12, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01112722"},{"key":"bibr45-11795514211006071","unstructured":"ClinicalTrials.gov, Christopher MH. Evaluate safety and efficacy of apitox add-on therapy for improving disability and quality of life in MS patients. National Library of Medicine (US). Identifier [NCT03710655]. 2018. Accessed August 12, 2020 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710655"},{"key":"bibr46-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a021889"},{"key":"bibr47-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2014.962518"},{"key":"bibr48-11795514211006071","first-page":"1077","volume":"16","author":"Xu J","year":"2006","journal-title":"Oncol Rep"},{"key":"bibr49-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2016.11.009"},{"key":"bibr50-11795514211006071","unstructured":"China Approval no. H53022101. Yunnan Nanzhao Pharmaceutical Co., Ltd."},{"key":"bibr51-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1039\/C6AN00327C"},{"key":"bibr52-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/BF02427280"},{"key":"bibr53-11795514211006071","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i15.1285"},{"key":"bibr54-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2013.09.009"},{"key":"bibr55-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.8.7628397"},{"key":"bibr56-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13018"},{"key":"bibr57-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42531-8"},{"key":"bibr58-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(94)90085-X"},{"key":"bibr59-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(80)35127-0"},{"key":"bibr60-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1949.sp004364"},{"key":"bibr61-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2018.12.004"},{"key":"bibr62-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1097\/00006534-198908000-00027"},{"key":"bibr63-11795514211006071","first-page":"543","volume":"289","author":"McArdle JJ","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr64-11795514211006071","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S84940"},{"key":"bibr65-11795514211006071","author":"Mabrouk K","year":"2018","journal-title":"WO\/2014\/037111 patent application"},{"key":"bibr66-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.08.023"},{"key":"bibr67-11795514211006071","unstructured":"Pandey A, Jatana GK, Sonthalia S. Cosmeceuticals. In: StatPearls [Internet]. StatPearls Publishing; 2020. Updated August 10, 2020. Accessed July 15, 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544223\/"},{"key":"bibr68-11795514211006071","volume-title":"Drug Discovery Approaches for Developing Cosmeceuticals: Advanced Skin Care and Cosmetic Products","author":"Hammes C.","year":"1997"},{"key":"bibr69-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(81)90370-2"},{"key":"bibr70-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(86)90145-2"},{"key":"bibr71-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1210\/endo.132.4.8462485"},{"key":"bibr72-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49658-0"},{"key":"bibr73-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.04.079"},{"key":"bibr74-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.02.077"},{"key":"bibr75-11795514211006071","unstructured":"ClinicalTrials.gov, Neutel J. Safety study of cenderitide in stable chronic heart failure. National Library of Medicine (US) Identifier [NCT02359227]. 2015. Accessed July 1, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02359227?term=NCT02359227&draw=2&rank=1"},{"key":"bibr76-11795514211006071","unstructured":"ClinicalTrials.gov, Schirger J. CD-NP (cenderitide) therapy for the preservation of left ventricular function (BELIEVE III). National Library of Medicine (US) Identifier [NCT02071602]. 2019. Accessed July 1, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02071602"},{"key":"bibr77-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(91)90462-R"},{"key":"bibr78-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-1236-7_10"},{"key":"bibr79-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5560010505"},{"key":"bibr80-11795514211006071","first-page":"141","volume":"31","author":"Toombs C.","year":"2001","journal-title":"Haemostasis"},{"key":"bibr81-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1159\/000092427"},{"key":"bibr82-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2009.08.053"},{"key":"bibr83-11795514211006071","unstructured":"ClinicalTrials.gov, Begelman SM. Phase 2 proof-of-concept study of the safety and efficacy of alfimeprase to rapidly open arteries and restore brain function following a stroke. National Library of Medicine (US) Identifier [NCT00499902]. 2007. Accessed July 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00499902?term=NCT00499902&draw=2&rank=1"},{"key":"bibr84-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/bi034043e"},{"key":"bibr85-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.08.001"},{"key":"bibr86-11795514211006071","unstructured":"Australian New Zealand Clinical Trials Registry, Herd C. A randomised, placebo-controlled, double-blind, single and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous doses of ACV1 in healthy adult male subjects. Identifier [ACTRN12605000408684]. 2005. Accessed July 3, 2020. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=468&isReview=true"},{"key":"bibr87-11795514211006071","unstructured":"Australian New Zealand Clinical Trials Registry, Herd C. A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of subcutaneous doses of ACV1 in patients with diabetic peripheral neuropathic pain or post-herpetic neuralgia. Identifier [ACTRN12607000201471]. 2007. Accessed July 3, 2020. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=81930&isReview=true"},{"key":"bibr88-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/md16120460"},{"key":"bibr89-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/toxins12080505"},{"key":"bibr90-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M003619200"},{"key":"bibr91-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M213101200"},{"key":"bibr92-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/jm9003413"},{"key":"bibr93-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.20.13752"},{"key":"bibr94-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00011"},{"key":"bibr95-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2013.00036"},{"key":"bibr96-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.253"},{"key":"bibr97-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(91)90155-5"},{"key":"bibr98-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000166050.84056.48"},{"key":"bibr99-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000049764.49162.76"},{"key":"bibr100-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70267-9"},{"key":"bibr101-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00047-2"},{"key":"bibr102-11795514211006071","unstructured":"ClinicalTrials.gov, Lundbeck H. Efficacy and safety study of desmoteplase to treat acute ischemic stroke (DIAS-4). National Library of Medicine (US) Iden-tifier [NCT00856661]. 2014. Accessed August 13, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00856661"},{"key":"bibr103-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1993.264.2.C361"},{"key":"bibr104-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/toxins7041079"},{"key":"bibr105-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(91)90128-E"},{"key":"bibr106-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-14-05942.1999"},{"key":"bibr107-11795514211006071","unstructured":"ClinicalTrials.gov, Badie B. Chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain for the treatment of MPP2+ recurrent or progressive glioblastoma. National Library of Medicine (US) Identifier [NCT04214392]. 2020. Accessed July 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04214392?term=NCT04214392&draw=2&rank=1"},{"key":"bibr108-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2127"},{"key":"bibr109-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0368-9"},{"key":"bibr110-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3171\/2013.11.FOCUS13497"},{"key":"bibr111-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyz125"},{"key":"bibr112-11795514211006071","unstructured":"ClinicalTrials.gov, Leary S. Study of tozuleristide and the canvas imaging system in pediatric subjects with CNS tumors undergoing surgery. National Library of Medicine (US) Identifier [NCT03579602]. 2020. Accessed July 2, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03579602?term=NCT03579602&draw=2&rank=1"},{"key":"bibr113-11795514211006071","doi-asserted-by":"publisher","DOI":"10.7150\/jca.31640"},{"key":"bibr114-11795514211006071","first-page":"1432","volume":"39","author":"Song H","year":"2018","journal-title":"Oncol Rep"},{"key":"bibr115-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0438-z"},{"key":"bibr116-11795514211006071","unstructured":"ClinicalTrials.gov, Ilenchuk TT. Safety and tolerability study of SOR-C13 in subjects with advanced cancers commonly known to express the TRPV6 channel. National Library of Medicine (US) Identifier [NCT01578564]. 2012. Accessed July 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01578564?term=NCT01578564&draw=2&rank=1"},{"key":"bibr117-11795514211006071","unstructured":"ClinicalTrials.gov Fu S. SOR-C13 in treating patients with advanced refractory solid tumors. National Library of Medicine (US) Identifier [NCT03784677]. 2012. Accessed July 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03784677?term=NCT03784677&draw=2&rank=1"},{"key":"bibr118-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0041-0101(95)00013-C"},{"key":"bibr119-11795514211006071","unstructured":"ClinicalTrials.gov, Iadonato S. Multiple ascending dose safety study of ShK-186 (dalazatide) in healthy volunteers. National Library of Medicine (US) Identifier [NCT02446340]. 2013. Accessed July 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02446340?term=NCT02446340&draw=2&rank=1"},{"key":"bibr120-11795514211006071","unstructured":"ClinicalTrials.gov, Iadonato S. A 4 week study of the safety, tolerability, and pharmacodynamics of ShK-186 (dalazatide) in active plaque psoriasis. National Library of Medicine (US) Identifier [NCT02435342]. 2014. Accessed July 5, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02435342?term=NCT02435342&draw=2&rank=1"},{"key":"bibr121-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v27.i4.10"},{"key":"bibr122-11795514211006071","author":"Reid PF","year":"2010","journal-title":"11\/592896 application number"},{"key":"bibr123-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(90)90407-I"},{"key":"bibr124-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2014.10.020"},{"key":"bibr125-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2018.01.004"},{"key":"bibr126-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114009"},{"key":"bibr127-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12432"},{"key":"bibr128-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4711-2"},{"key":"bibr129-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.03.024"},{"key":"bibr130-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110006"},{"key":"bibr131-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.11.012"},{"key":"bibr132-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1201\/b22121-3"},{"key":"bibr133-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55080436"},{"key":"bibr134-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2017.06.004"},{"key":"bibr135-11795514211006071","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.12.2270"},{"key":"bibr136-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00202"},{"key":"bibr137-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.07.001"},{"key":"bibr138-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1042\/bj0530366"},{"key":"bibr139-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1423857112"},{"key":"bibr140-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3292"},{"key":"bibr141-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0430-8"},{"key":"bibr142-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500064200"},{"key":"bibr143-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201200218"},{"key":"bibr144-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.77"},{"key":"bibr145-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308450100"},{"key":"bibr146-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1221206110"},{"key":"bibr147-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2017.05.027"},{"key":"bibr148-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05134-3"},{"key":"bibr149-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040942"},{"key":"bibr150-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600351R"},{"key":"bibr151-11795514211006071","first-page":"840","volume":"4","author":"Sola D","year":"2015","journal-title":"Arch Med Res"},{"key":"bibr152-11795514211006071","volume":"362","author":"Douros A","year":"2018","journal-title":"BMJ"},{"key":"bibr153-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.201200081"},{"key":"bibr154-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/jm401904q"},{"key":"bibr155-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2015.05.002"},{"key":"bibr156-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(82)90409-5"},{"key":"bibr157-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2004.10.017"},{"key":"bibr158-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)47710-1"},{"key":"bibr159-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1007\/s10930-004-0601-1"},{"key":"bibr160-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(98)00226-8"},{"key":"bibr161-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-1459fje"},{"key":"bibr162-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2003.03563.x"},{"key":"bibr163-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.27.1942"},{"key":"bibr164-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)92779-4"},{"key":"bibr165-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2012.05.027"},{"key":"bibr166-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(71)90045-2"},{"key":"bibr167-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1112828109"},{"key":"bibr168-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00246"},{"key":"bibr169-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119071"},{"key":"bibr170-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32169"},{"key":"bibr171-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.10.016"},{"key":"bibr172-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1111\/1748-5967.12431"},{"key":"bibr173-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1186\/s41936-019-0127-x"},{"key":"bibr174-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/biom5010194"},{"key":"bibr175-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2014.09.034"},{"key":"bibr176-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.95.6.1041"},{"key":"bibr177-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205532200"},{"key":"bibr178-11795514211006071","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0991"},{"key":"bibr179-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)38560-6"},{"key":"bibr180-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-24-09585.2001"},{"key":"bibr181-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80306-2"},{"key":"bibr182-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/0079-6107(89)90013-8"},{"key":"bibr183-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2017.01.032"},{"key":"bibr184-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1021\/acs.langmuir.8b01076"},{"key":"bibr185-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.07.010"},{"key":"bibr186-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(02)00595-8"},{"key":"bibr187-11795514211006071","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.04.06.db05-0788"},{"key":"bibr188-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.201812213"},{"key":"bibr189-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.119"},{"key":"bibr190-11795514211006071","doi-asserted-by":"publisher","DOI":"10.3390\/toxins2122851"},{"key":"bibr191-11795514211006071","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0053-0"}],"container-title":["Clinical Medicine Insights: Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795514211006071","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795514211006071","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795514211006071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:06:36Z","timestamp":1777406796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795514211006071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":191,"alternative-id":["10.1177\/11795514211006071"],"URL":"https:\/\/doi.org\/10.1177\/11795514211006071","relation":{},"ISSN":["1179-5514","1179-5514"],"issn-type":[{"value":"1179-5514","type":"print"},{"value":"1179-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"11795514211006071"}}